Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement

Ludger Klimek¹, Marek Jutel², Cezmi Akdis³, Jean Bousquet^{4

5

6

7}, Mübeccel Akdis³, Claus Bachert⁸, Ioana Agache⁹, Ignacio Ansotegui¹⁰, Anna Bedbrook⁶, Sinthia Bosnic-Anticevich¹¹, Giorgio W Canonica^{12

13}, Tomas Chivato^{14

15}, Alvaro A Cruz¹⁶, Wienia Czarlewski¹⁷, Stefano Del Giacco¹⁸, Hui Du¹⁹, Joao A Fonseca^{20

21}, Yadong Gao¹⁹, Tari Haahtela^{22

23

24

25}, Karin Hoffmann-Sommergruber²⁶, Juan-Carlos Ivancevich²⁷, Nikolai Khaltaev²⁸, Edward F Knol²⁹, Piotr Kuna³⁰, Desiree Larenas-Linnemann³¹, Erik Melen³², Joaquim Mullol^{33

34}, Robert Naclerio³⁵, Ken Ohta³⁶, Yoshitaka Okamoto³⁷, Liam O'Mahony³⁸, Gabrielle L Onorato⁶, Nikos G Papadopoulos³⁹, Ruby Pawankar⁴⁰, Oliver Pfaar⁴¹, Boleslaw Samolinski⁴², Jurgen Schwarze⁴³, Sanna Toppila-Salmi^{21

22

23

24}, Mohamed H Shamji⁴⁴, Maria Teresa Ventura^{45

46}, Arunas Valiulis⁴⁷, Arzu Yorgancioglu^{48

49}, Paolo Matricardi⁵⁰, Torsten Zuberbier^{51

52}; ARIA-MASK Study Group

Affiliations

¹ Center for Rhinology and Allergology, Wiesbaden, Germany.
² Department of Clinical Immunology, Wrocław Medical University, ALL-MED Medical Research Institute, Wrocław, Poland.
³ Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
⁴ Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany.
⁵ University Hospital Montpellier, Montpellier, France.
⁶ MACVIA-France, Montpellier, France.
⁷ Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium.
⁸ Transylvania University Brasov, Brasov, Romania.
⁹ Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain.
¹⁰ Woolcock Institute of Medical Research, University of Sydney, Woolcock Emphysema Centre, Sydney Local Health District, Glebe, NSW, Australia.
¹¹ Personalized Medicine, Asthma and Allergy - Humanitas Clinical and Research Center IRCCS, Rozzano, MI, Italy.
¹² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
¹³ School of Medicine, University CEU San Pablo, Madrid, Spain.
¹⁴ ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Bahia, Brazil.
¹⁵ WHO GARD Planning Group, Bahia, Brazil.
¹⁶ Medical Consulting Czarlewski, Levallois, and MASK-air, Montpellier, France.
¹⁷ Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital "Duilio Casula", University of Cagliari, Cagliari, Italy.
¹⁸ Department of Respiratory Medicine, Wuhan Children's Hospital, Tongji Medical College, Huazhong, China.
¹⁹ University of Science and Technology, Wuhan, China.
²⁰ Center for Research in Health Technologies and Information Systems- CINTESIS, Universidade do Porto, Porto, Portugal.
²¹ Allergy Unit, Instituto CUF Porto e Hospital CUF Porto, Porto, Portugal.
²² Health Information and Decision Sciences Department - CIDES, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
²³ Faculdade de Medicina da Universidade do Porto, Porto, Portugal.
²⁴ Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.
²⁵ Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.
²⁶ Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.
²⁷ GARD Chairman, Geneva, Switzerland.
²⁸ Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.
²⁹ Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.
³⁰ Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.
³¹ Institute of Environmental Medicine, Karolinska Institutet and Sachs' Children's Hospital, Stockholm, Sweden.
³² Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain.
³³ Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.
³⁴ Johns Hopkins School of Medicine, Baltimore, MD, USA.
³⁵ National Hospital Organization, Tokyo National Hospital, Tokyo, Japan.
³⁶ Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.
³⁷ Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.
³⁸ Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital,, University of Manchester, Manchester, UK.
³⁹ Department of Pediatrics, Nippon Medical School, Tokyo, Japan.
⁴⁰ Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Marburg, Germany.
⁴¹ Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Germany.
⁴² Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.
⁴³ Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.
⁴⁴ Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.
⁴⁵ Vilnius University Faculty of Medicine, Institute of Clinical Medicine & Institute of Health Sciences, Vilnius, Lithuania.
⁴⁶ European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium.
⁴⁷ Department of Pulmonology, Celal Bayar University, Manisa, Turkey.
⁴⁸ Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁴⁹ Department of Dermatology and Allergy, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Berlin, Germany.
⁵⁰ Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK.
⁵¹ Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.
⁵² Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.

PMID: 32329930
PMCID: PMC7264744
DOI: 10.1111/all.14336

Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement

Ludger Klimek et al. Allergy. 2020 Jul.

. 2020 Jul;75(7):1546-1554.

doi: 10.1111/all.14336.

Authors

Affiliations

¹ Center for Rhinology and Allergology, Wiesbaden, Germany.
² Department of Clinical Immunology, Wrocław Medical University, ALL-MED Medical Research Institute, Wrocław, Poland.
³ Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
⁴ Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany.
⁵ University Hospital Montpellier, Montpellier, France.
⁶ MACVIA-France, Montpellier, France.
⁷ Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium.
⁸ Transylvania University Brasov, Brasov, Romania.
⁹ Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain.
¹⁰ Woolcock Institute of Medical Research, University of Sydney, Woolcock Emphysema Centre, Sydney Local Health District, Glebe, NSW, Australia.
¹¹ Personalized Medicine, Asthma and Allergy - Humanitas Clinical and Research Center IRCCS, Rozzano, MI, Italy.
¹² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
¹³ School of Medicine, University CEU San Pablo, Madrid, Spain.
¹⁴ ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Bahia, Brazil.
¹⁵ WHO GARD Planning Group, Bahia, Brazil.
¹⁶ Medical Consulting Czarlewski, Levallois, and MASK-air, Montpellier, France.
¹⁷ Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital "Duilio Casula", University of Cagliari, Cagliari, Italy.
¹⁸ Department of Respiratory Medicine, Wuhan Children's Hospital, Tongji Medical College, Huazhong, China.
¹⁹ University of Science and Technology, Wuhan, China.
²⁰ Center for Research in Health Technologies and Information Systems- CINTESIS, Universidade do Porto, Porto, Portugal.
²¹ Allergy Unit, Instituto CUF Porto e Hospital CUF Porto, Porto, Portugal.
²² Health Information and Decision Sciences Department - CIDES, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
²³ Faculdade de Medicina da Universidade do Porto, Porto, Portugal.
²⁴ Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.
²⁵ Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.
²⁶ Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina.
²⁷ GARD Chairman, Geneva, Switzerland.
²⁸ Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.
²⁹ Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.
³⁰ Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico.
³¹ Institute of Environmental Medicine, Karolinska Institutet and Sachs' Children's Hospital, Stockholm, Sweden.
³² Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain.
³³ Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain.
³⁴ Johns Hopkins School of Medicine, Baltimore, MD, USA.
³⁵ National Hospital Organization, Tokyo National Hospital, Tokyo, Japan.
³⁶ Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan.
³⁷ Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.
³⁸ Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital,, University of Manchester, Manchester, UK.
³⁹ Department of Pediatrics, Nippon Medical School, Tokyo, Japan.
⁴⁰ Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Marburg, Germany.
⁴¹ Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Germany.
⁴² Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.
⁴³ Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.
⁴⁴ Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy.
⁴⁵ Vilnius University Faculty of Medicine, Institute of Clinical Medicine & Institute of Health Sciences, Vilnius, Lithuania.
⁴⁶ European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium.
⁴⁷ Department of Pulmonology, Celal Bayar University, Manisa, Turkey.
⁴⁸ Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁴⁹ Department of Dermatology and Allergy, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Berlin, Germany.
⁵⁰ Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK.
⁵¹ Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.
⁵² Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.

PMID: 32329930
PMCID: PMC7264744
DOI: 10.1111/all.14336

Abstract

formula image

Keywords: allergy treatment; immunotherapy clinical; immunotherapy vaccines and mechanisms.

PubMed Disclaimer

Conflict of interest statement

LK declares grants and/or personal fees from Allergopharma, MEDA/Mylan, LETIPharma, Sanofi, HAL Allergie, Allergy Therapeutics, ALK Abelló, Stallergenes, Quintiles, ASIT biotech, Lofarma, AstraZeneca, GSK, Inmunotek, and is a current member of the AeDA, DGHN, Deutsche Akademie fürAllergologie und KlinischeImmunologie, HNO‐BV GPA, and EAACI. MJ reports personal fees from ALK‐Abelló, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, LETIPharma, Biomay, HAL Allergy, AstraZeneca, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, Medimmune, and Chiesi. CA reports grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Research and Education, European Commission's Horizon's 2020 Framework Programme, Cure, Novartis Research Institutes, AstraZeneca, SciBase, and advisory role in Sanofi/Regeneron. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi‐Aventis, Takeda, Teva, Uriach, and others from KYomed INNOV. CB has received fees for delivering lectures. IA declares personal fees from Mundipharma, ROXALL, Sanofi, MSD, Faes Farma, Hikma, UCB, and AstraZeneca. B‐A reports grants and/or personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, and Mylan. AC reports grants and/or personal fees from GSK, AstraZeneca, Mylan Pharma, Boehringer Ingelheim, and Sanofi. TH reports personal fees from GSK, Mundipharma, and Orion Pharma. J‐CI received personal fees from Eurofarma Argentina, Faes Farma, and nonfinancial support from Laboratorio Casasco Argentina and Sanofi. PK has received personal fees from Adamed, Berlin Chemie Menarini, AstraZeneca, Boehringer Ingelheim, Chiesi, Lekam, Novartis, Orion, Polpharma, and Teva. DL‐L reports personal fees and/or grants from Allakos, Amstrong, AstraZeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grünenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Gossamer, TEVA, Boehringer Ingelheim, and the Purina institute. JM declares fees and/or grants from Sanofi‐Genzyme, Regeneron, Novartis, Allakos grants, Mylan Pharma, Uriach Group, Mitsubishi‐Tanabe, Menarini, UCB, AstraZeneca, GSK, and MSD. RN serves in the speaker's bureau for Optinose and as consultant/advisory board for Sanofi, Regeneron, GSK, and AstraZeneca. YO reports personal fees and/or grants from Shionogi Co., Ltd., Torii Co., Ltd., GSK, MSD, EizaiCo.,Ltd., Kyorin Co., Ltd., Tiho Co., Ltd., Yakuruto Co., Ltd., and Yamada Bee Farm. NP has received personal fees and/or grants from Novartis, Nutricia, HAL Allergy, Menarini/Faes Farma, Sanofi, Mylan/MEDA, Biomay, AstraZeneca, GSK, MSD, ASIT biotech, Boehringer Ingelheim, Gerolymatos International SA, and Capricare. OP reports grants and/or personal fees from ASIT Biotech Tools SA, Laboratorios LETI/LETI Pharma, Anergis SA, ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, BencardAllergie GmbH/Allergy Therapeutics, Lofarma, Biomay, Circassia, MEDA Pharma/Mylan, Mobile Chamber Experts (a GA²LEN Partner), Indoor Biotechnologies, GSK, Astellas Pharma Global, EUFOREA, ROXALL, Novartis, and Sanofi Aventis. JS reports personal fees from Mylan. MHS has received grants and/or personal fees from ALK, Allergopharma, ASIT Biotech, Regeneron, Merck, Immune Tolerance Network. TZ serves as a member of the WHO‐Initiative "Allergic Rhinitis and Its Impact on Asthma" (ARIA), the German Society for Allergy and Clinical Immunology (DGAKI), head of the European Centre for Allergy Research Foundation (ECARF), president of the Global Allergy and Asthma European Network (GA²LEN), and serves in the committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). All other authors have no conflict of interest within the scope of the submitted work.

References

1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in wuhan, china, of novel coronavirus‐infected pneumonia. N Engl J Med. 2020;382(13):1199‐1207. - PMC - PubMed
1. Zhu NA, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727‐733. - PMC - PubMed
1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses . The species Severe acute respiratory syndrome‐related coronavirus. classifying 2019‐nCoV and naming it SARS‐CoV‐2. Nat Microbiol. 2020;5(4):536‐544. - PMC - PubMed
1. Zhang J‐J, Dong X, Cao Y‐Y, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy 2020. 10.1111/all.14238. [Epub ahead of print] - DOI - PubMed
1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418‐423. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement

Affiliations

Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement

Authors

Affiliations

Abstract

Conflict of interest statement

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical